Table 1.
Independent genetic variants with suggestive interactions of current MHT use on breast cancer risk after LD-based clumping.
| SNP rsida | Chr | Positiona | A1 | A2 | EAF | Nearby genes | OR | 95% CI | P-value |
|---|---|---|---|---|---|---|---|---|---|
| rs4674019 | 2 | 216601295 | A | G | 0.05 | LINC00607 | 0.74 | (0.66, 0.83) | 2.27E−07 |
| rs12600110 | 16 | 962154 | T | C | 0.38 | LMF1 | 1.14 | (1.08, 1.20) | 5.11E−07 |
| rs548302406 | 2 | 120097151 | T | TA | 0.35 | C2orf76 | 0.86 | (0.81, 0.92) | 8.03E−07 |
| rs117199302 | 11 | 77378563 | T | C | 0.02 | RSF1 | 0.60 | (0.49, 0.73) | 8.82E−07 |
| rs150004705 | 7 | 147063496 | A | G | 0.01 | CNTNAP2 | 0.57 | (0.46, 0.72) | 9.13E−07 |
| rs188419699 | 7 | 6674441 | G | A | 0.99 | ZNF853 | 0.40 | (0.27, 0.58) | 2.16E−06 |
| rs12600110 | 2 | 189608701 | C | T | 0.99 | DIRC1, LOC105373790 | 0.48 | (0.36, 0.66) | 3.26E−06 |
| rs11738429 | 5 | 36167878 | G | A | 0.19 | SKP2 | 1.17 | (1.09, 1.25) | 4.09E−06 |
| rs13121484 | 4 | 182999291 | A | G | 0.33 | AC108142.1 | 1.14 | (1.08, 1.21) | 5.02E−06 |
| rs74617030 | 2 | 206040628 | G | GA | 0.55 | PARD3B | 1.13 | (1.07, 1.19) | 5.90E−06 |
| rs146251672 | 3 | 64290001 | G | C | 0.98 | PRICKLE2, LRRN1 | 1.50 | (1.26, 1.78) | 6.08E−06 |
| rs560643086 | 1 | 204318668 | C | CA | 0.75 | PLEKHA6 | 1.16 | (1.09, 1.24) | 6.46E−06 |
| rs79001083 | 8 | 106538183 | A | C | 0.05 | ZFPM2 | 1.30 | (1.16, 1.46) | 7.12E−06 |
| rs7900145 | 10 | 4933685 | T | G | 0.24 | AKR1C6P | 1.15 | (1.08, 1.22) | 7.75E−06 |
| rs375101296 | 11 | 78180810 | C | CAG | 0.94 | NARS2 | 0.77 | (0.69, 0.86) | 8.23E−06 |
| rs72692777 | 9 | 10011536 | T | C | 0.02 | PTPRD | 0.70 | (0.59, 0.82) | 8.86E−06 |
| rs142227065 | 4 | 132518511 | T | TA | 0.001 | RP11-314N14.1 | 0.22 | (0.11, 0.43) | 9.07E−06 |
| rs10015072 | 4 | 31386277 | T | C | 0.836 | RP11-315A17.1 | 1.18 | (1.10, 1.27) | 9.67E−06 |
Chr chromosome, A1 reference allele, A2 alternative allele, EAF estimated allele frequency for alternative allele, OR odds ratios error per alternative allele with current menopausal hormone therapy use on breast cancer risk, 95% CI corresponding 95% confidence intervals.
arsid and position are based on the Genome Reference Consortium Human genome build 37.